Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    Darvadstrocel

    go.drugbank.com/drugs/DB16581
    ApprovedInvestigationalWithdrawn

    Perianal fistula is a common manifestation of Crohn’s disease and is often difficult to manage, as it may be associated with complex presentations and symptoms. … It is indicated for the treatment of complex perianal fistulas in adult patients with non-active or mildly active luminal Crohn’s disease when fistulas have shown an inadequate response to at least one

  2. Drug

    Merbromin

    go.drugbank.com/drugs/DB13392
    Investigational

    due to the possibility of mercury poisoning. … Mercurochrome is a trade name of merbromin commonly used as a topical first-aid antiseptic agent.

    Products: BERKOMER SOLUSYON, 50 ML
  3. Drug

    Technetium Tc-99m tilmanocept

    go.drugbank.com/drugs/DB09266
    Approved

    It is a macromolecule consisting of multiple units of diethylenetriaminepentaacetic acid (DTPA) and mannose, each covalently attached to a 10 kDa dextran backbone [FDA Label]. … Due to its relatively small molecular weight and small molecular diameter of 7 nm [A32168], technetium Tc-99m tilmanocept displays more rapid injection site clearance, high sentinel node extraction, and

  4. Drug

    Efanesoctocog alfa

    go.drugbank.com/drugs/DB16662
    ApprovedInvestigational

    Endogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [L45379] The use of FVIII replacement products is beneficial in patients with hemophilia A; however, their quality of life can be affected due to frequent doses.

  5. Drug

    Afamitresgene autoleucel

    go.drugbank.com/drugs/DB18592
    ApprovedInvestigational

    Afamitresgene autoleucel is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy product consisting of CD4 and CD8 positive T cells transduced with a … LV containing the MAGE-A4 TCR transgene.

    Synonyms: HUMAN MELANOMA ANTIGEN A4 (MAGE FAMILY MEMBER A4, A, AUTOLOGOUS CD4+ AND CD8+ T CELLS OBTAINED BY LEUKAPHERESIS, TRANSDUCED WITH AN HIV-DERIVED SELF-INACTIVATING (SIN) LENTIVIRAL VECTOR, ENCODING AN ENHANCED-AFFINITY T CELL RECEPTOR (TCR) SPECIFIC FOR THE
  6. Drug

    Inbakicept

    go.drugbank.com/drugs/DB16479
    Investigational

    Inbakicept is a dimeric human IL-15 receptor α (IL-15Rα) sushi domain/human IgG1 Fc fusion protein. … [A263617, A263622] Inbakicept, in combination with nogapendekin alfa, mimics the actions of IL-15, stimulating the activation and proliferation of natural killer cells and CD8+ memory T cells, which also

    Synonyms: INTERLEUKIN 15 RECEPTOR .ALPHA. CHAIN (HUMAN SUSHI DOMAIN-CONTAINING FRAGMENT) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN FC FRAGMENT), DIMER, IGHG1*01, HINGE (71-80), CH2 (81-190), CH3 (191-2Categories: Interleukin-15, Receptors, Interleukin-15
  7. Drug

    Amcipatricin

    go.drugbank.com/drugs/DB12333
    Investigational

    SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone … Amcipatricin (as amcipatricin diascorbate; SPK-843) is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment

  8. Drug

    Ublituximab

    go.drugbank.com/drugs/DB11850
    ApprovedInvestigational

    [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … CD20, an antigen expressed by various B and T cells, is an attractive therapeutic target in various cancers and autoimmune conditions.

  9. Drug

    Vepdegestrant

    go.drugbank.com/drugs/DB19006
    ApprovedInvestigational

    [A275507, A275508, A275511] It was identified through a targeted medicinal chemistry optimization campaign to act as a next-generation endocrine therapy for breast cancer. … [A275507, A275509] It serves as an advanced option to address the clinical challenge of endocrine-resistant breast cancer subtypes.

    Categories: Cytochrome P-450 CYP2B6 Inhibitors, Cytochrome P-450 Substrates
  10. Drug

    Maralixibat

    go.drugbank.com/drugs/DB16226
    ApprovedInvestigational

    Maralixibat (also known as SHP625, LUM001, and lopixibat) is an ileal bile acid transporter inhibitor, like [odevixibat]. … [A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also been used as treatments.

    Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 Inhibitors